Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Hadassah Medical Center: Gabizon Ruth

Last updated December 2021 - Hadassah Medical Center

List of Publications

(1) Binyamin O, Frid K, Keller G, Saada A, Gabizon R. Comparing anti–aging hallmark activities of Metformin and Nano-PSO in a mouse model of genetic Creutzfeldt-Jakob Disease. Neurobiol Aging 2022;110:77-87.

(2) Binyamin O, Nitzan K, Frid K, Ungar Y, Rosenmann H, Gabizon R. Author Correction: Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice (Scientific Reports, (2019), 9, 1, (18437), 10.1038/s41598-019-54971-9). Sci Rep 2020;10(1).

(3) Frid K, Binyamin O, Usman A, Gabizon R. Delay of gCJD aggravation in sick TgMHu2ME199K mice by combining NPC transplantation and Nano-PSO administration. Neurobiol Aging 2020;95:231-239.

(4) Friedman-Levi Y, Binyamin O, Frid K, Ovadia H, Gabizon R. Erratum: Genetic prion disease: No role for the immune system in disease pathogenesis? (Human Molecular Genetics (2014) 23:15 (4134-4141) DOI: 10.1093/hmg/ddu134). Hum Mol Genet 2020;29(6):1055.

(5) Binyamin O, Nitzan K, Frid K, Ungar Y, Rosenmann H, Gabizon R. Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice. Sci Rep 2019;9(1).

(6) Keller G, Binyamin O, Frid K, Saada A, Gabizon R. Mitochondrial dysfunction in preclinical genetic prion disease: A target for preventive treatment? Neurobiol Dis 2019;124:57-66.

(7) Frid K, Binyamin O, Fainstein N, Keller G, Ben-Hur T, Gabizon R. Autologous neural progenitor cell transplantation into newborn mice modeling for E200K genetic prion disease delays disease progression. Neurobiol Aging 2018;65:192-200.

(8) Lasmézas C, Gabizon R. Identifying therapeutic targets and treatments in model systems. Handb Clin Neurol 2018;153:409-418.

(9) Binyamin O, Keller G, Frid K, Larush L, Magdassi S, Gabizon R. Continues administration of Nano-PSO significantly increased survival of genetic CJD mice. Neurobiol Dis 2017;108:140-147.

(10) Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J, et al. Erratum: Correction: Oxidation of Helix-3 Methionines Precedes the Formation of PK Resistant PrPSc (PLoS pathogens (2010) 6 7 (e1000977)). PLoS Pathog 2017;13(5):e1006293.

(11) Friedman-Levi Y, Meiner Z, Canello T, Frid K, Kovacs GG, Budka H, et al. Erratum: Correction: Fatal Prion Disease in a Mouse Model of Genetic E200K Creutzfeldt-Jakob Disease (PLoS pathogens (2011) 7 11 (e1002350)). PLoS Pathog 2017;13(5):e1006294.

(12) Fainstein N, Dori D, Frid K, Fritz AT, Shapiro I, Gabizon R, et al. Chronic progressive neurodegeneration in a transgenic mouse model of prion disease. Front Neurosci 2016;10(NOV).

(13) Binyamin O, Larush L, Frid K, Keller G, Friedman-Levi Y, Ovadia H, et al. Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant. Int J Nanomed 2015;10:7165-7174.

(14) Friedman-Levi Y, Mizrahi M, Frid K, Binyamin O, Gabizon R. Erratum: PrPST, a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease (PLoS ONE (2013) 8:7 (e69583) DOI: 10.1371/journal.pone.0069583). PLoS ONE 2015;10(7).

(15) Frid K, Einstein O, Friedman-Levi Y, Binyamin O, Ben-Hur T, Gabizon R. Aggregation of MBP in chronic demyelination. Ann Clin Transl Neurol 2015;2(7):711-721.

(16) Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, et al. Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: The case of genetic CJD. Nanomed Nanotechnol Biol Med 2014;10(6):1353-1363.

(17) Friedman-Levi Y, Binyamin O, Frid K, Ovadia H, Gabizon R. Genetic prion disease: No role for the immune system in disease pathogenesis? Hum Mol Genet 2014;23(15):4134-4141.

(18) Friedman-Levi Y, Mizrahi M, Frid K, Binyamin O, Gabizon R. PrPST, a Soluble, Protease Resistant and Truncated PrP Form Features in the Pathogenesis of a Genetic Prion Disease. PLoS ONE 2013;8(7).

(19) Cohen E, Avrahami D, Frid K, Canello T, Levy Lahad E, Zeligson S, et al. Snord 3A: A Molecular Marker and Modulator of Prion Disease Progression. PLoS ONE 2013;8(1).

(20) Tzour A, Sosial E, Meir T, Canello T, Naveh-Many T, Gabizon R, et al. Multiple Pathways for High Voltage-Activated Ca2+ Influx in Anterior Pituitary Lactotrophs and Somatotrophs. J Neuroendocrinol 2013;25(1):76-86.

(21) Friedman-Levi Y, Hoftberger R, Budka H, Mayer-Sonnenfeld T, Abramsky O, Ovadia H, et al. Targeting of prion-infected lymphoid cells to the central nervous system accelerates prion infection. J Neuroinflamm 2012;9.

(22) Canello T, Friedman-Levi Y, Mizrahi M, Binyamin O, Cohen E, Frid K, et al. Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse model of E200K genetic prion disease. Neurobiol Dis 2012;45(3):1010-1017.

(23) Avrahami D, Gabizon R. Age-related alterations affect the susceptibility of mice to prion infection. Neurobiol Aging 2011;32(11):2006-2015.

(24) Meiner Z, Kahana E, Baitcher F, Korczyn AD, Chapman J, Cohen OS, et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol 2011;258(2):255-262.

(25) Friedman-Levi Y, Meiner Z, Canello T, Frid K, Kovacs GG, Budka H, et al. Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease. PLoS Pathog 2011;7(11).

(26) Lisa S, Meli M, Cabello G, Gabizon R, Colombo G, Gasset M. The structural intolerance of the PrP α-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci 2010;67(16):2825-2838.

(27) Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J, et al. Oxidation of Helix-3 methionines precedes the formation of PK resistant PrPSc. PLoS Pathog 2010;6(7):1-10.

(28) Oien DB, Canello T, Gabizon R, Gasset M, Lundquist BL, Burns JM, et al. Detection of oxidized methionine in selected proteins, cellular extracts and blood serums by novel anti-methionine sulfoxide antibodies. Arch Biochem Biophys 2009;485(1):35-40.

(29) Colombo G, Meli M, Morra G, Gabizon R, Gasset M. Methionine sulfoxides on prion protein helix-3 switch on the α-fold destabilization required for conversion. PLoS ONE 2009;4(1).

(30) Avrahami D, Dayan-Amouyal Y, Tal S, Mincberg M, Davis C, Abramsky O, et al. Virus-induced alterations of membrane lipids affect the incorporation of PrPSc into cells. J Neurosci Res 2008;86(12):2753-2762.

(31) Mayer-Sonnenfeld T, Avrahami D, Friedman-Levi Y, Gabizon R. Chemically induced accumulation of GAGs delays PrPSc clearance but prolongs prion disease incubation time. Cell Mol Neurobiol 2008;28(7):1005-1015.

(32) Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes ME, Langeveld J, et al. Methionine sulfoxides on PrPSc: A prion-specific covalent signature 1. Biochemistry 2008;47(34):8866-8873.

(33) Haviv Y, Avrahami D, Ovadia H, Ben-Hur T, Gabizon R, Sharon R. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch Neurol 2008;65(6):762-775.

(34) Petrakis S, Irinopoulou T, Panagiotidis CH, Engelstein R, Lindstrom J, Orr-Urtreger A, et al. Cellular prion protein co-localizes with nAChR β4 subunit in brain and gastrointestinal tract (European Journal of Neuroscience (2007) 27, (612-620)). Eur J Neurosci 2008;27(8):2212.

(35) Petrakis S, Irinopoulou T, Panagiotidis CH, Engelstein R, Lindstrom J, Orr-Urtreger A, et al. Cellular prion protein co-localizes with nAChR β4 subunit in brain and gastrointestinal tract. Eur J Neurosci 2008;27(3):612-620.

(36) Friedman-Levi Y, Ovadia H, Hoftberger R, Einstein O, Abramsky O, Budka H, et al. Fatal neurological disease in scrapie-infected mice induced for experimental autoimmune encephalomyelitis. J Virol 2007;81(18):9942-9949.

(37) Engelstein R, Ovadia H, Gabizon R. Copaxone interferes with the PrPSc-GAG interaction. Eur J Neurol 2007;14(8):877-884.

(38) Kariv-Inbal Z, Ben-Hur T, Grigoriadis NC, Engelstein R, Gabizon R. Urine from scrapie-infected hamsters comprises low levels of prion infectivity. Neurodegenerative Dis 2006;3(3):123-128.

(39) Halimi M, Dayan-Amouyal Y, Kariv-Inbal Z, Friedman-Levi Y, Mayer-Sonnenfeld T, Gabizon R. Prion urine comprises a glycosaminoglycan-light chain IgG complex that can be stained by Congo red. J Virol Methods 2006;133(2):205-210.

(40) Mayer-Sonnenfeld T, Zeigler M, Halimi M, Dayan Y, Herzog C, Lasmezas CI, et al. The metabolism of glycosaminoglycans is impaired in prion diseases. Neurobiol Dis 2005;20(3):738-743.

(41) Hijazi N, Kariv-Inbal Z, Gasset M, Gabizon R. PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem 2005;280(17):17057-17061.

(42) Kariv-Inbal Z, Halimi M, Dayan Y, Engelstein R, Gabizon R. Characterization of light chain immunoglobulin in urine from animals and humans infected with prion diseases. J Neuroimmunol 2005;162(1-2):12-18.

(43) Engelstein R, Grigoriadis N, Greig NH, Ovadia H, Gabizon R. Inhibition of P53-related apoptosis had no effect on PrPSc accumulation and prion disease incubation time. Neurobiol Dis 2005;18(2):282-285.

(44) Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T, Gabizon R. Copper binding to PrPC may inhibit prion disease propagation. Brain Res 2003;993(1-2):192-200.

(45) Schonberger O, Horonchik L, Gabizon R, Papy-Garcia D, Barritault D, Taraboulos A. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem Biophys Res Commun 2003;312(2):473-479.

(46) Shaked GM, Engelstein R, Avraham I, Kahana E, Gabizon R. Dimethyl sulfoxide delays PrPsc accumulation and disease symptoms in prion-infected hamsters. Brain Res 2003;983(1-2):137-143.

(47) Shaked Y, Hijazi N, Gabizon R. Doppel and PrPC do not share the same membrane microenvironment. FEBS Lett 2002;530(1-3):85-88.

(48) Tzaban S, Friedlander G, Schonberger O, Horonchik L, Yedidia Y, Shaked G, et al. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry 2002;41(42):12868-12875.

(49) Shaked GM, Engelstein R, Avraham I, Rosenmann H, Gabizon R. Valproic acid treatment results in increased accumulation of prion proteins. Ann Neurol 2002;52(4):416-420.

(50) Shaked Y, Engelstein R, Gabizon R. The binding of prion proteins to serum components is affected by detergent extraction conditions. J Neurochem 2002;82(1):1-5.

(51) Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R. A Protease-resistant Prion Protein Isoform Is Present in Urine of Animals and Humans Affected with Prion Diseases. J Biol Chem 2001;276(34):31479-31482.

(52) Shaked Y, Rosenmann H, Hijazi N, Halimi M, Gabizon R. Copper binding to the PrP isoforms: A putative marker of their conformation and function. J Virol 2001;75(17):7872-7874.

(53) Shaked GM, Meiner Z, Avraham I, Taraboulos A, Gabizon R. Reconstitution of Prion Infectivity from Solubilized Protease-resistant PrP and Nonprotein Components of Prion Rods. J Biol Chem 2001;276(17):14324-14328.

(54) Rosenmann H, Talmor G, Halimi M, Yanai A, Gabizon R, Meiner Z. Prion protein with an E200K mutation displays properties similar to those of the cellular isoform PrPC. J Neurochem 2001;76(6):1654-1662.

(55) Keshet GI, Bar-Peled O, Yaffe D, Nudel U, Gabizon R. The cellular prion protein colocalizes with the dystroglycan complex in the brain. J Neurochem 2000;75(5):1889-1897.

(56) Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H, et al. Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200k mutation. Ann Neurol 2000;47(2):257-260.

(57) Shaked Y, Rosenmann H, Talmor G, Gabizon R. A C-terminal-truncated PrP isoform is present in mature sperm. J Biol Chem 1999;274(45):32153-32158.

(58) Yanai A, Meiner Z, Gahali I, Gabizon R, Taraboulos A. Subcellular trafficking abnormalities of a prion protein with a disrupted disulfide loop. FEBS Lett 1999;460(1):11-16.

(59) Rosenmann H, Kahana E, Korczyn AD, Kahana I, Chapman J, Gabizon R. Preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease. Neurology 1999;53(6):1328-1329.

(60) Shaked GM, Fridlander G, Meiner Z, Taraboulos A, Gabizon R. Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity. J Biol Chem 1999;274(25):17981-17986.

(61) Keshet GI, Ovadia H, Taraboulos A, Gabizon R. Scrapie-infected mice and PrP knockout mice share abnormal localization and activity of neuronal nitric oxide synthase. J Neurochem 1999;72(3):1224-1231.

(62) Meiner Z, Gabizon R. A new variant of Creutzfeldt-Jakob disease and its relation to bovine spongiform encephalopathy (BSE) in Great Britain. Harefuah 1998;134(6):465-468.

(63) Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 1998;273(6):3484-3489.

(64) Rosenmann H, Vardi J, Finkelstein Y, Chapman J, Gabizon R. Identification in Israel of 2 Jewish Creutzfeldt-Jakob disease patients with a 178 mutation at their PrP gene. Acta Neurol Scand 1998;97(3):184-187.

(65) Gabizon R, Taraboulos A. Of mice and (mad) cows - Transgenic mice help to understand prions. Trends Genet 1997;13(7):264-269.

(66) Friedman G, Gabizon R, Ben-Yehuda A. Apolipoprotein Eε4 allele, a risk factor for late onset nonfamilial Alzheimer's disease among Israeli Jews. Arch Gerontol Geriatr 1997;24(2):175-181.

(67) Meiner Z, Gabizon R, Prusiner SB. Familial Creutzfeldt-Jakob Disease Codon 200 Prion Disease in Libyan Jews. Medicine 1997;76(4):227-237.

(68) Rosenmann H, Halimi M, Kahana I, Biran I, Gabizon R. Differential allelic expression of PrP mRNA in carriers of the E200K mutation. Neurology 1997;49(3):851-856.

(69) Rosenmann H, Meiner Z, Kahana E, Halimi M, Lenetsky E, Abramsky O, et al. Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt Jakob disease. Neurology 1997;49(2):593-595.

(70) Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996;274(5295):2079-2082.

(71) Ovadia H, Rosenmann H, Shezen E, Halimi M, Ofran I, Gabizon R. Effect of scrapie infection on the activity of neuronal nitric-oxide synthase in brain and neuroblastoma cells. J Biol Chem 1996;271(28):16856-16861.

(72) Gabizon R, Telling G, Meiner Z, Halimi M, Kahana I, Prusiner SB. Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Nat Med 1996;2(1):59-64.

(73) Kaneko K, Peretz D, Pan K-, Blochberger TC, Wille H, Gabizon R, et al. Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci U S A 1995;92(24):11160-11164.

(74) Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995;83(1):79-90.

(75) Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I, et al. Complete penetrance of Cruetzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1995;1(6):607-613.

(76) Gabizon R, Rosenman H, Meiner Z, Kahana I, Kahana E, Shugart Y, et al. Mutation in codon 200 and polymorphism in codon 129 of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease. Philos Trans R Soc Lond , B, Biol Sci 1994;343(1306):385-390.

(77) Gabizon R, Halimi M, Meiner Z. Genetics and biochemistry of Creutzfeldt-Jakob disease in Libyan Jews. Biomed Pharmacother 1994;48(8-9):385-390.

(78) Prusiner SB, Groth D, Serban A, Stahl N, Gabizon R. Attempts to restore scrapie prion infectivity after exposure to protein denaturants. Proc Natl Acad Sci U S A 1993;90(7):2793-2797.

(79) Goldhammer Y, Gabizon R, Meiner Z, Sadeh M. An israeli family with gerstmann-straussler-scheinker disease manifesting the codon 102 mutation in the prion protein gene. Neurology 1993;43(12):2718-2719.

(80) Gabizon R, Meiner Z, Halimi M, Ben‐Sasson SA. Heparin‐like molecules bind differentially to prion‐proteins and change their intracellular metabolic fate. J Cell Physiol 1993;157(2):319-325.

(81) Gabizon R, Rosenmann H, Meiner Z, Kahana I, Kahana E, Shugart Y, et al. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am J Hum Genet 1993;53(4):828-835.

(82) Meiner Z, Halimi M, Polakiewicz RD, Prusiner SB, Gabizon R. Presence of prion protein in peripheral tissues of libyan jews with Creutzfeldt-Jakob disease. Neurology 1992;42(7):1355-1360.

(83) Hsiao K, Meiner Z, Kahana E, Cass C, Kahana I, Avrahami D, et al. Mutation of the prion protein in libyan jews with creutzfeldt–jakob disease. New Engl J Med 1991;324(16):1091-1097.

(84) Meiner Z, Gabizon R, Kahana E. Creutzfeldt-Jacob disease: etiology and epidemiology. Harefuah 1991;120(1):19-22.

(85) Gabizon R, Prusiner SB. Prion liposomes. Biochem J 1990;266(1):1-14.

(86) Gabizon R, McKinley MP, Groth D, Westaway D, DeArmond SJ, Carlson GA, et al. Immunoaffinity purification and neutralization of scrapie prions. Prog Clin Biol Res 1989;317:583-600.

(87) Gabizon R, McKinley MP, Groth DF, Kenaga L, Prusiner SB. Properties of scrapie prion protein liposomes. J Biol Chem 1988;263(10):4950-4955.

(88) Bellinger-Kawahara CG, Kempner E, Groth D, Gabizon R, Prusiner SB. Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology 1988;164(2):537-541.

(89) Gabizon R, McKinley MP, Prusiner SB. Properties of scrapie prion proteins in liposomes and amyloid rods. Ciba Found Symp 1988;135:182-196.

(90) Gabizon R, McKinley MP, Groth D, Prusiner SB. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci U S A 1988;85(18):6617-6621.

(91) Prusiner SB, Gabizon R, McKinley MP. On the biology of prions. Acta Neuropathol 1987;72(4):299-314.

(92) Gabizon R, McKinley MP, Prusiner SB. Purified prion proteins and scrapie infectivity copartition into liposomes. Proc Natl Acad Sci U S A 1987;84(12):4017-4021.

(93) SCHULDINER S, GABIZON R, STERN Y, SUCHI R. The Amine Transporter from Bovine Chromaffin Granules: Photolabeling and Partial Purification. Ann New York Acad Sci 1987;493(1):189-193.

(94) SCHULDINER S, GABIZON R, MARON R, SUCHI R, STERN Y. The Amine Transporter from Bovine Chromaffin Granules. Ann New York Acad Sci 1985;456(1):268-276.

(95) Gabizon R, Schuldiner S. The amine transporter from bovine chromaffin granules. Partial purification. J Biol Chem 1985;260(5):3001-3005.

(96) Gabizon R, Yetinson T, Schuldiner S. Photoinactivation and identification of the biogenic amine transporter in chromaffin granules from bovine adrenal medulla. J Biol Chem 1982;257(24):15145-15150.